Category: Health Science
-
![Medexus (MDP.V) by Mackie Research upgrades their target price by 42%]()
Medexus (MDP.V) by Mackie Research upgrades their target price by 42%
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech is not an easy industry to understand. The jargon used by those writing about the industry often takes away from the ingenious business models of some…
-
![The top 10 most cashed up psychedelics companies right now]()
The top 10 most cashed up psychedelics companies right now
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes hundreds of millions of dollars. And that’s only part of the picture. According to Tufts Center for the Study of Drug Development, bringing a new FDA-approved drug…
-
Psychedelic Weekly Roundup with MNMD.Q, MSET.C, MYND.C, MEDI.NE, AWKN.NE, SILO, MCUR.C, NOVA.C, TRYP.C, TPIA, NEON.C
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine (MNMD.Q, MMED.NE) MindMed announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate to…
-
![Bioasis Technologies (BTI.V): To Invest or Not?]()
Bioasis Technologies (BTI.V): To Invest or Not?
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary…
-
![Bioasis (BTI.V) revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain]()
Bioasis (BTI.V) revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain
Bioasis is a preclinical biopharmaceutical company focused on research and early-stage development of technologies and products for the treatment of patients with the central nervous system, or CNS, diseases, and disorders. In layman’s terms, this is a company that researches and develops products for the diagnosis and treatment of neurological diseases and disorders. The company…
-
![Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)]()
Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical…
-
![Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q]()
Psyched for this weeks news from CYBN.NE, PSYC.C, MNMD.Q, MSET.C, FTRP.Q, MYCO.NE, RVV.C, FH.NE, CMND.C, ATAI.Q
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been a busy week for Cybin. Last week, after market close, they released their financials for the quarter ending on June 30, 2021, which showed they had…
-
![Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor]()
Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor
Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8 million in cash and cash equivalents. This includes $5 million which was raised through a private placement that closed on June 21. That private placement included…
-
![Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?]()
Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible. Filament Health (FH.NEO) is an exclusively natural psychedelic drug development company and received the first-ever psilocybin extraction and standardization patent for a public company…
-
![Filament Health (FH.NE): the natural psychedelic company flying under the radar]()
Filament Health (FH.NE): the natural psychedelic company flying under the radar
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which contains DMT, was given out by shamans in the Amazon as a tea. It was a spiritual experience that would purge you of your negative energy…
